Ligand Pharmaceuticals Inc. scored the first direct hit from its decades-long collaboration with Pfizer Inc. as the FDA approved Duavee (conjugated estrogens/bazedoxifene) in a once-daily 0.45-mg/20-mg tablet form. The drug, formerly known as Aprela, is indicated for moderate to severe vasomotor symptoms – commonly known as hot flashes – associated with menopause and for the prevention of postmenopausal osteoporosis.